705
Participants
Start Date
May 31, 2006
Primary Completion Date
June 30, 2007
Study Completion Date
June 30, 2007
Semuloparin sodium
"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
Placebo (for Enoxaparin sodium)
"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
Enoxaparin sodium
"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
Placebo (for Semuloparin sodium)
"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
Sanofi-Aventis Administrative Office, Buenos Aires
Sanofi-Aventis Administrative Office, Sofia
Sanofi-Aventis Administrative Office, Santiago
Sanofi-Aventis Administrative Office, Bogotá
Sanofi-Aventis Administrative Office, Hørsholm
Sanofi-Aventis Administrative Office, Helsinki
Sanofi-Aventis Administrative Office, Athens
Sanofi-Aventis Administrative Office, Kuala Lumpur
Sanofi-Aventis Administrative Office, México
Sanofi-Aventis Administrative Office, Lysaker
Sanofi-Aventis Administrative Office, Makati City
Sanofi-Aventis Administrative Office, Warsaw
Sanofi-Aventis Administrative Office, Porto Salvo
Sanofi-Aventis Administrative Office, Bucharest
Sanofi-Aventis Administrative Office, Moscow
Sanofi-Aventis Administrative Office, Bromma
Sanofi-Aventis Administrative Office, Taipei
Sanofi-Aventis Administrative Office, Bangkok
Sanofi-Aventis Administrative Office, Istanbul
Lead Sponsor
Sanofi
INDUSTRY